Aurora Cannabis Inc. (ACB)
USD 4.24
(-5.15%)
USD 4.24
(-5.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 20.47 Million CAD | 109.72% |
| 2022 | -210.74 Million CAD | -47.28% |
| 2021 | -143.08 Million CAD | -4.29% |
| 2020 | -137.2 Million CAD | 65.11% |
| 2019 | -393.23 Million CAD | -83.19% |
| 2018 | -214.66 Million CAD | -173.61% |
| 2017 | -78.45 Million CAD | -504.3% |
| 2016 | -12.98 Million CAD | -173.38% |
| 2015 | -4.74 Million CAD | 48.61% |
| 2014 | -9.24 Million CAD | -2997.78% |
| 2013 | -298.32 Thousand CAD | 25.87% |
| 2012 | -402.44 Thousand CAD | -21.82% |
| 2011 | -330.36 Thousand CAD | -78.23% |
| 2010 | -185.36 Thousand CAD | -224.15% |
| 2009 | -57.18 Thousand CAD | 60.43% |
| 2008 | -144.51 Thousand CAD | 36.77% |
| 2007 | -228.55 Thousand CAD | -18243.26% |
| 2006 | -1246.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | 12.53 Million CAD | 120.26% |
| 2023 Q2 | -7.86 Million CAD | -162.72% |
| 2023 Q3 | 16.31 Million CAD | 307.41% |
| 2023 FY | - CAD | 109.72% |
| 2022 Q3 | -15.91 Million CAD | 70.45% |
| 2022 Q4 | -61.89 Million CAD | -288.84% |
| 2022 Q2 | -53.86 Million CAD | -40.5% |
| 2022 Q1 | -38.33 Million CAD | 38.06% |
| 2022 FY | - CAD | -47.28% |
| 2021 Q4 | -61.89 Million CAD | -18.56% |
| 2021 Q1 | 1.03 Million CAD | -30.45% |
| 2021 FY | - CAD | -4.29% |
| 2021 Q2 | -30.02 Million CAD | -2994.89% |
| 2021 Q3 | -52.2 Million CAD | -73.91% |
| 2020 Q4 | 1.49 Million CAD | 101.22% |
| 2020 Q1 | -14.62 Million CAD | 91.41% |
| 2020 Q2 | -2.1 Million CAD | 85.6% |
| 2020 FY | - CAD | 65.11% |
| 2020 Q3 | -121.96 Million CAD | -5691.31% |
| 2019 Q3 | -52.34 Million CAD | 38.92% |
| 2019 Q4 | -170.23 Million CAD | -225.21% |
| 2019 Q2 | -85.69 Million CAD | -78.05% |
| 2019 Q1 | -48.12 Million CAD | -176.04% |
| 2019 FY | - CAD | -83.19% |
| 2018 Q4 | 63.29 Million CAD | 143.23% |
| 2018 FY | - CAD | -173.61% |
| 2018 Q1 | -88.48 Million CAD | -146.36% |
| 2018 Q2 | -49.3 Million CAD | 44.28% |
| 2018 Q3 | -146.41 Million CAD | -196.95% |
| 2017 Q1 | -1.56 Million CAD | 76.41% |
| 2017 Q4 | -35.91 Million CAD | -24.83% |
| 2017 FY | - CAD | -504.3% |
| 2017 Q3 | -28.77 Million CAD | -104.15% |
| 2017 Q2 | -14.09 Million CAD | -802.88% |
| 2016 Q3 | -1.31 Million CAD | 33.19% |
| 2016 Q2 | -1.96 Million CAD | 36.37% |
| 2016 FY | - CAD | -173.38% |
| 2016 Q4 | -6.61 Million CAD | -404.01% |
| 2016 Q1 | -3.08 Million CAD | 57.1% |
| 2015 FY | - CAD | 48.61% |
| 2015 Q4 | -7.19 Million CAD | -357.8% |
| 2015 Q3 | 2.79 Million CAD | 246.54% |
| 2015 Q2 | 805.75 Thousand CAD | 176.05% |
| 2015 Q1 | -1.05 Million CAD | -103.65% |
| 2014 Q2 | -5.71 Million CAD | -1048.38% |
| 2014 Q1 | -497.25 Thousand CAD | -277.0% |
| 2014 Q4 | 29 Million CAD | 3371.48% |
| 2014 FY | - CAD | -2997.78% |
| 2014 Q3 | -886.59 Thousand CAD | 84.47% |
| 2013 FY | - CAD | 25.87% |
| 2013 Q4 | -131.89 Thousand CAD | -39.63% |
| 2013 Q3 | -94.46 Thousand CAD | -207.69% |
| 2013 Q1 | -41.26 Thousand CAD | 61.48% |
| 2013 Q2 | -30.7 Thousand CAD | 25.6% |
| 2012 Q3 | -75.09 Thousand CAD | -6.73% |
| 2012 FY | - CAD | -21.82% |
| 2012 Q1 | -148.61 Thousand CAD | 30.37% |
| 2012 Q2 | -70.36 Thousand CAD | 52.65% |
| 2012 Q4 | -107.13 Thousand CAD | -42.66% |
| 2011 FY | - CAD | -78.23% |
| 2011 Q3 | -41.42 Thousand CAD | -6.88% |
| 2011 Q1 | -44.41 Thousand CAD | 58.32% |
| 2011 Q2 | -38.75 Thousand CAD | 12.74% |
| 2011 Q4 | -213.45 Thousand CAD | -415.29% |
| 2010 Q1 | -37.64 Thousand CAD | 39.08% |
| 2010 FY | - CAD | -224.15% |
| 2010 Q4 | -106.56 Thousand CAD | -185.07% |
| 2010 Q3 | -37.38 Thousand CAD | 14.04% |
| 2010 Q2 | -43.49 Thousand CAD | -15.53% |
| 2009 Q2 | -13.15 Thousand CAD | 46.99% |
| 2009 Q1 | -24.81 Thousand CAD | -43.29% |
| 2009 Q3 | -13.65 Thousand CAD | -3.8% |
| 2009 Q4 | -61.79 Thousand CAD | -352.57% |
| 2009 FY | - CAD | 60.43% |
| 2008 Q1 | -92.15 Thousand CAD | -129.03% |
| 2008 Q2 | -32.19 Thousand CAD | 65.07% |
| 2008 Q4 | -17.31 Thousand CAD | 41.03% |
| 2008 FY | - CAD | 36.77% |
| 2008 Q3 | -29.36 Thousand CAD | 8.79% |
| 2007 Q3 | -22.09 Thousand CAD | 86.59% |
| 2007 Q4 | -40.23 Thousand CAD | -82.07% |
| 2007 Q2 | -164.79 Thousand CAD | -11464.7% |
| 2007 Q1 | -1425.00 CAD | 0.0% |
| 2007 FY | - CAD | -18243.26% |
| 2006 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | 298.53% |
| Harrow Health, Inc. | 9.72 Million USD | -110.573% |
| Dynavax Technologies Corporation | 9.66 Million USD | -111.815% |
| Biofrontera Inc. | -18.45 Million USD | 210.952% |
| Cronos Group Inc. | -72.14 Million USD | 128.377% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 552.464% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 102.214% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 156.743% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 22.052% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 2980.214% |
| Radius Health, Inc. | 38.31 Million USD | 46.557% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 736.814% |
| DURECT Corporation | -24.68 Million USD | 182.944% |
| ProPhase Labs, Inc. | -14.82 Million USD | 238.086% |
| Safety Shot Inc | -12.18 Million USD | 268.024% |
| Phibro Animal Health Corporation | 84.6 Million USD | 75.801% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 970.86% |
| Alvotech | -484.86 Million USD | 104.223% |
| Assertio Holdings, Inc. | -222.44 Million USD | 109.204% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 79.164% |
| Rockwell Medical, Inc. | -4.69 Million USD | 536.174% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 635.349% |
| Procaps Group S.A. | 104.02 Million USD | 80.319% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 112.889% |
| SCYNEXIS, Inc. | 73.47 Million USD | 72.136% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 2123.123% |
| Viatris Inc. | 3.51 Billion USD | 99.418% |
| OptiNose, Inc. | -15.55 Million USD | 231.64% |
| SIGA Technologies, Inc. | 84.15 Million USD | 75.672% |
| Tilray Brands, Inc. | -72.84 Million USD | 128.107% |
| PetIQ, Inc. | 81.48 Million USD | 74.874% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 635.349% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 95.08% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 621.982% |
| Alimera Sciences, Inc. | 7.27 Million USD | -181.391% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 93.36% |
| Silver Spike Investment Corp. | 7.34 Million USD | -178.933% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 613.049% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 43.177% |
| Journey Medical Corporation | 1.92 Million USD | -965.799% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 586.102% |
| Alpha Teknova, Inc. | -25.53 Million USD | 180.168% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 221.84% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -2421.429% |
| PainReform Ltd. | -9.56 Million USD | 313.962% |
| Cosmos Health Inc. | -17.06 Million USD | 219.999% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 113.729% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 343.709% |
| Embecta Corp. | 245.4 Million USD | 91.657% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 665.951% |
| Talphera, Inc. | -9.84 Million USD | 308.027% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 87.431% |
| Incannex Healthcare Limited | -18.5 Million USD | 210.646% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 202.213% |
| Shineco, Inc. | -26.55 Million USD | 177.104% |
| Procaps Group, S.A. | 104.02 Million USD | 80.319% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 81.271% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -1632.149% |
| Lantheus Holdings, Inc. | 491 Million USD | 95.83% |
| Alvotech | -484.86 Million USD | 104.223% |
| Hempacco Co., Inc. | -12.77 Million USD | 260.288% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 73.583% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 113.64% |
| Kamada Ltd. | 21.53 Million USD | 4.922% |
| Indivior PLC | 66 Million USD | 68.979% |
| Evoke Pharma, Inc. | -7.29 Million USD | 380.762% |
| Flora Growth Corp. | -45.87 Million USD | 144.635% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 202.213% |
| Evolus, Inc. | -41.81 Million USD | 148.969% |
| HUTCHMED (China) Limited | 25.52 Million USD | 19.798% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 91.521% |
| Akanda Corp. | -27.73 Million USD | 173.818% |